Form 4: Nuvation Bio CFO Granted 748K Stock Options

Nuvation Bio Inc.'s Chief Financial Officer, Philippe Sauvage, was granted 748,130 stock options with an exercise price of $5.91, vesting over four years.

Summary

• Philippe Sauvage, Chief Financial Officer of Nuvation Bio Inc., reported changes in beneficial ownership.
• Sauvage was granted 748,130 stock options to purchase Class A Common Stock on February 27, 2026.
• The exercise price for these options is $5.91 per share.
• The options begin vesting as to 25% on February 27, 2027 (the one-year anniversary of the grant date), and monthly thereafter over the subsequent 36 months, contingent on continuous service.
• The options have an expiration date of February 26, 2036.
• Sauvage also beneficially owns 12,673 shares of Class A Common Stock, which includes 2,771 shares acquired on November 19, 2025, under the 2021 Employee Stock Purchase Plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it demonstrates continued executive commitment and alignment with shareholder interests through long-term equity incentives, which is a standard and healthy practice.

Positives

• The grant of a significant number of stock options (748,130) to the Chief Financial Officer indicates management's continued alignment with shareholder interests and a long-term commitment to the company's performance.
• The vesting schedule over four years encourages long-term retention and performance from a key executive.

Risks

• The value of the stock options is dependent on the future performance of Nuvation Bio Inc.'s stock price exceeding the $5.91 exercise price.
• The vesting schedule requires continuous service, meaning the options could be forfeited if the CFO leaves the company before full vesting.

Future Outlook

The vesting schedule for the granted stock options extends over four years, indicating a long-term incentive structure tied to the company's future performance and the executive's continued tenure.

Management Comments

• No direct management comments or quotes are provided in this Form 4 filing, which is a transactional disclosure.

Industry Context

StockSavvy.ai notes that executive stock option grants are a standard practice in the biotechnology and pharmaceutical industries, particularly for growth-stage companies like Nuvation Bio. These grants are designed to align executive incentives with long-term shareholder value creation, encouraging executives to drive innovation and achieve clinical and commercial milestones. The size of the grant is substantial, reflecting the importance of the CFO role in financial strategy and capital management within a capital-intensive industry.

Comparison to Industry Standards

• The grant of stock options with a multi-year vesting schedule is a common compensation practice for C-suite executives in the biotech sector, comparable to practices at companies like Moderna or BioNTech, where executive compensation often includes significant equity components to incentivize long-term value creation.
• The exercise price of $5.91 per share reflects the market price at the time of the grant, a standard approach for 'at-the-money' options, similar to grants observed at peer companies such as Relay Therapeutics or Revolution Medicines.
• The total number of options granted (748,130) is a significant equity stake, aligning with the compensation packages for CFOs at similarly sized or growth-stage biopharmaceutical companies, where equity often forms a substantial portion of total compensation to retain talent and motivate performance in a highly competitive industry.

Related Party Transactions

• The stock option grant to the Chief Financial Officer is a transaction between the company and an executive, which is a form of related-party transaction, but it is a standard compensation practice disclosed as required.

Stakeholder Impact

• Shareholders: The grant aligns the CFO's interests with shareholders by incentivizing long-term stock price appreciation. Dilution from future option exercises is a potential, but expected, consequence of equity compensation plans.
• Employees: This grant is part of the overall executive compensation strategy, which can influence morale and retention across the organization.

Next Steps

• Continued vesting of the granted stock options over the next four years, subject to the CFO's continuous service.
• Potential exercise of vested options by the CFO in the future, depending on stock performance and personal financial planning.

Key Dates

Recommendation

This Form 4 filing details a routine stock option grant to a key executive, which is a standard compensation practice. It does not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The grant itself is a positive for executive alignment but is not a catalyst for a 'buy' or 'sell' decision.

Keywords

Nuvation Bio, NUVB, Form 4, Insider Trading, Stock Options, Executive Compensation, Philippe Sauvage, CFO, Equity Grant, Beneficial Ownership